Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 6.52
TLRY's Cash-to-Debt is ranked lower than
96% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. TLRY: 6.52 )
Ranked among companies with meaningful Cash-to-Debt only.
TLRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.46 Max: 6.52
Current: 6.52
0.05
6.52
Equity-to-Asset 0.84
TLRY's Equity-to-Asset is ranked lower than
97% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TLRY: 0.84 )
Ranked among companies with meaningful Equity-to-Asset only.
TLRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.09  Med: 0.37 Max: 0.84
Current: 0.84
-0.09
0.84
Debt-to-Equity 0.10
TLRY's Debt-to-Equity is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. TLRY: 0.10 )
Ranked among companies with meaningful Debt-to-Equity only.
TLRY' s Debt-to-Equity Range Over the Past 10 Years
Min: -10.56  Med: 1.23 Max: 11.35
Current: 0.1
-10.56
11.35
Debt-to-EBITDA -0.53
TLRY's Debt-to-EBITDA is ranked lower than
99.99% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. TLRY: -0.53 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TLRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.07  Med: -7.35 Max: -0.53
Current: -0.53
-9.07
-0.53
Altman Z-Score: 167.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -114.14
TLRY's Operating Margin % is ranked lower than
81% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. TLRY: -114.14 )
Ranked among companies with meaningful Operating Margin % only.
TLRY' s Operating Margin % Range Over the Past 10 Years
Min: -114.14  Med: -46.13 Max: -36.51
Current: -114.14
-114.14
-36.51
Net Margin % -121.12
TLRY's Net Margin % is ranked lower than
80% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. TLRY: -121.12 )
Ranked among companies with meaningful Net Margin % only.
TLRY' s Net Margin % Range Over the Past 10 Years
Min: -121.12  Med: -50.19 Max: -38.02
Current: -121.12
-121.12
-38.02
ROE % -75.86
TLRY's ROE % is ranked lower than
99.99% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. TLRY: -75.86 )
Ranked among companies with meaningful ROE % only.
TLRY' s ROE % Range Over the Past 10 Years
Min: -311.83  Med: -311.83 Max: -75.86
Current: -75.86
-311.83
-75.86
ROA % -40.36
TLRY's ROA % is ranked lower than
77% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. TLRY: -40.36 )
Ranked among companies with meaningful ROA % only.
TLRY' s ROA % Range Over the Past 10 Years
Min: -40.36  Med: -20.88 Max: -17.94
Current: -40.36
-40.36
-17.94
ROC (Joel Greenblatt) % -78.29
TLRY's ROC (Joel Greenblatt) % is ranked lower than
71% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. TLRY: -78.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TLRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -78.29  Med: -27.25 Max: -23.42
Current: -78.29
-78.29
-23.42
GuruFocus has detected 1 Warning Sign with Tilray Inc TLRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TLRY's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TLRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Tilray Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325411    SIC: 2833
Compare: » details
Traded in other countries:2HQ.Germany, 2HQ.Switzerland,
Headquarter Location:


Top Ranked Articles about Tilray Inc

US Market Indexes Close Higher After Four Days of Losses Dow Jones closes at 26,439.93 with a gain of 0.21%
The Dow Jones Industrial Average closed at 26,439.93 on Thursday for a gain of 54.65 points or 0.21%. The S&P 500 closed at 2,914.00 for a gain of 8.03 points or 0.28%. The Nasdaq Composite closed at 8,041.97 for a gain of 34.50 points or 0.43%. The VIX Volatility Index was lower at 12.42 for a loss of -0.47 points or -3.65%. Read more...
Dow Jones Closes at 26,405.76 on Wednesday US market indexes mostly higher, Nasdaq falls
The Dow Jones Industrial Average closed at 26,405.76 on Wednesday with a gain of 158.80 points or 0.61%. The S&P 500 closed at 2,907.95 for a gain of 3.64 points or 0.13%. The Nasdaq Composite closed at 7,950.04 for a loss of -6.07 points or -0.08%. The VIX Volatility Index was lower at 11.75 for a loss of -1.04 points or -8.13%. Read more...
Thinking about buying stock in Canopy Growth, Coca-Cola Co., Constellation Brands, Molson Coors Brewing, or Tilray Inc.?
US Market Indexes Close Higher on Tuesday Nasdaq Composite closes at 7,972.47 with a gain of 0.61%
The Dow Jones Industrial Average closed at 25,971.06 on Tuesday with a gain of 113.99 points or 0.44%. The S&P 500 closed at 2,887.89 for a gain of 10.76 points or 0.37%. The Nasdaq Composite closed at 7,972.47 with a gain of 48.31 points or 0.61%. The VIX Volatility Index was lower at 13.22 for a loss of -0.94 points or -6.64%. Read more...
Weekly CFO Buys Highlight Insiders invest in Tilray, a REIT and Provention Bio
According to GuruFocus Insider Data, the recent chief financial officer buys were Tilray Inc. (NASDAQ:TLRY), Investors Real Estate Trust (NYSE:IRET) and Provention Bio Inc. (NASDAQ:PRVB). Read more...

Ratios

vs
industry
vs
history
PB Ratio 48.13
TLRY's PB Ratio is ranked lower than
99.99% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. TLRY: 48.13 )
Ranked among companies with meaningful PB Ratio only.
TLRY' s PB Ratio Range Over the Past 10 Years
Min: 38.56  Med: 54.69 Max: 73.42
Current: 48.13
38.56
73.42
PS Ratio 272.87
TLRY's PS Ratio is ranked lower than
99.99% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TLRY: 272.87 )
Ranked among companies with meaningful PS Ratio only.
TLRY' s PS Ratio Range Over the Past 10 Years
Min: 218.79  Med: 310.34 Max: 416.57
Current: 272.87
218.79
416.57
EV-to-EBIT -251.04
TLRY's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. TLRY: -251.04 )
Ranked among companies with meaningful EV-to-EBIT only.
TLRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -367.3  Med: -272.9 Max: -191.6
Current: -251.04
-367.3
-191.6
EV-to-EBITDA -272.99
TLRY's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. TLRY: -272.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
TLRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -399.4  Med: -296.8 Max: -208.4
Current: -272.99
-399.4
-208.4
EV-to-Revenue 286.54
TLRY's EV-to-Revenue is ranked lower than
94% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. TLRY: 286.54 )
Ranked among companies with meaningful EV-to-Revenue only.
TLRY' s EV-to-Revenue Range Over the Past 10 Years
Min: 218.7  Med: 311.5 Max: 419.2
Current: 286.54
218.7
419.2
Current Ratio 5.43
TLRY's Current Ratio is ranked lower than
98% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. TLRY: 5.43 )
Ranked among companies with meaningful Current Ratio only.
TLRY' s Current Ratio Range Over the Past 10 Years
Min: 0.25  Med: 0.62 Max: 5.43
Current: 5.43
0.25
5.43
Quick Ratio 4.98
TLRY's Quick Ratio is ranked lower than
99% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. TLRY: 4.98 )
Ranked among companies with meaningful Quick Ratio only.
TLRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.51 Max: 4.98
Current: 4.98
0.1
4.98
Days Inventory 132.59
TLRY's Days Inventory is ranked lower than
85% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. TLRY: 132.59 )
Ranked among companies with meaningful Days Inventory only.
TLRY' s Days Inventory Range Over the Past 10 Years
Min: 132.59  Med: 189.86 Max: 229.57
Current: 132.59
132.59
229.57
Days Sales Outstanding 64.11
TLRY's Days Sales Outstanding is ranked higher than
94% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. TLRY: 64.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
TLRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.21  Med: 14.84 Max: 64.11
Current: 64.11
12.21
64.11
Days Payable 198.14
TLRY's Days Payable is ranked higher than
86% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. TLRY: 198.14 )
Ranked among companies with meaningful Days Payable only.
TLRY' s Days Payable Range Over the Past 10 Years
Min: 27.7  Med: 124.68 Max: 221.65
Current: 198.14
27.7
221.65

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 109.15
TLRY's Price-to-Net-Cash is ranked lower than
99.99% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.41 vs. TLRY: 109.15 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TLRY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 106.44  Med: 161.37 Max: 161.37
Current: 109.15
106.44
161.37
Price-to-Net-Current-Asset-Value 82.32
TLRY's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. TLRY: 82.32 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TLRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 80.28  Med: 121.71 Max: 121.71
Current: 82.32
80.28
121.71
Price-to-Tangible-Book 48.33
TLRY's Price-to-Tangible-Book is ranked lower than
99.99% of the 749 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. TLRY: 48.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TLRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 47.13  Med: 71.63 Max: 71.63
Current: 48.33
47.13
71.63
Price-to-Median-PS-Value 0.88
TLRY's Price-to-Median-PS-Value is ranked lower than
99.99% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. TLRY: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TLRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.86  Med: 1.27 Max: 1.27
Current: 0.88
0.86
1.27
Earnings Yield (Greenblatt) % -0.40
TLRY's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. TLRY: -0.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TLRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.5  Med: -0.4 Max: -0.3
Current: -0.4
-0.5
-0.3

More Statistics

Revenue (TTM) (Mil) $32.71
EPS (TTM) $ -0.28
52-Week Range $20.10 - 300.00
Shares Outstanding (Mil)93.16

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 40 121 246 393
EBIT (Mil $)
EBITDA (Mil $) -24 -4 30 83
EPS ($) -0.43 -0.29 -0.10 0.83
EPS without NRI ($) -0.43 -0.29 -0.10 0.83
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}